Zacks.com on MSN5d
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...
Truist Financial Keeps Their Buy Rating on Nucana (NCNA)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Instil Bio, Inc. TIL shares dropped 25% to $63.50. The company announced the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in ...
NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...
Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.
bovnews6d
The Stunning Stock Surge of NuCana (NCNA): Analyzing the Impact of New Clinical Data
NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...
NuCana ADRs Nearly Double on Positive Data From Metastatic Melanoma Treatment
NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...
Yahoo Finance6d
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...
Yahoo Finance9d
NUCANA SP.ADR 25/ LS-,04 (N04.BE)
As of 10:10 CEST. Market open. Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: ...
Investing19d
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials
On Tuesday, Oppenheimer adjusted its outlook on NuCana (NASDAQ:NCNA), reducing the price target to $25.00 from the previous $150.00 while maintaining an Outperform rating. The revision follows last ...